ReviewCold Spring Harbor perspectives in medicine2014
Global epidemiology of tuberculosis.
Review in Cold Spring Harbor perspectives in medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 95 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
95 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Economic burden of multidrug-resistant tuberculosis on patients and households: a global systematic review and meta-analysis.Scientific reports · 2023Pooled it
- Pooled it
- Trial
- Burden of tuberculosis in Xinjiang between 2011 and 2015: A surveillance data-based study.PloS one · 2017Trial
- Spatiotemporal trends in tuberculosis incidence in Thailand, 2012-2023: a nationwide, province-level analysis.Infectious diseases of poverty · 2026Article
- Development of Isoniazid-Pyrazole Hybrids as Potential Antitubercular Agents.International journal of molecular sciences · 2026Article
- Biopsychosocial determinants of tuberculosis care and treatment outcomes: a scoping review and bibliometric analysis.Frontiers in cellular and infection microbiology · 2026Article
- Epidemiological trends and burden of mortality from HIV/AIDS and multidrug-resistant tuberculosis without extensive drug-resistance across Africa: A global burden of disease analysis (1990-2021).Journal of clinical tuberculosis and other mycobacterial diseases · 2025Article
- ESX-5 Deletions inbioRxiv : the preprint server for biology · 2025Article
- Treatment outcomes for drug-resistant tuberculosis: a retrospective longitudinal study.BMC infectious diseases · 2025Article
- Rationally Designed InhA Inhibitors: A Comparative Anti-Tubercular Activity Study of Sulfonate Esters of Isoniazid Hydrazones and Their Structurally Flexible Benzyl Analogues.Chemical biology & drug design · 2025Article
- Pulmonary Complications in Connective Tissue Disease-Associated Interstitial Lung Disease.The clinical respiratory journal · 2025Review
- Development ofMini reviews in medicinal chemistry · 2025Review
- Tuberculosis diagnosis using artificial intelligence: current trends and future prospects.Frontiers in medicine · 2025Review
- Trends and disparities in tuberculosis burden in Kazakhstan and Mongolia (2017-2021): a comparative analysis using GBD metrics.Frontiers in public health · 2025Article
- Bayesian estimation of the time-varying reproduction number for pulmonary tuberculosis in Iran: A registry-based study from 2018 to 2022 using new smear-positive cases.Infectious Disease Modelling · 2024Article
- Review
- Rising role of 3D-printing in delivery of therapeutics for infectious disease.Journal of controlled release : official journal of the Controlled Release Society · 2024Review
- Impact of Isoniazid Preventive Therapy on Tuberculosis Incidence and Predictors of Tuberculosis Among People Living With HIV/AIDS at Debre Tabor General Hospital, Northwest Ethiopia.Tuberculosis research and treatment · 2024Article
- The metabolic consequences of HIV/TB co-infection.BMC infectious diseases · 2023Article
35 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Despite the availability of effective chemotherapy, tuberculosis (TB) killed 1.3 million people in 2012. Alongside HIV, it remains a top cause of death from an infectious disease. Global targets for reductions in the epidemiological burden of TB have been set for 2015 and 2050 within the context of the Millennium Development Goals (MDGs) and by the Stop TB Partnership. Achieving these targets is the focus of national and international efforts in TB control, and showing whether or not they are achieved is of major importance to guide future and sustainable investments. This article provides a short overview of sources of data to estimate TB disease burden; presents estimates of TB incidence, prevalence, and mortality in 2012 and an assessment of progress toward the 2015 targets for reductions in these indicators based on trends since 1990 and projections up to 2015; analyzes trends in TB notifications and in the implementation of the Stop TB Strategy; and considers prospects for elimination of TB after 2015.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.